Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
| Index | Bloomberg MSCI USD Liquid Investment Grade Corporate SRI PAB (EUR Hedged) |
| Investment focus | Bonds, USD, World, Corporate, All maturities, Social/Environmental |
| Fund size | GBP 47 m |
| Total expense ratio | 0.21% p.a. |
| Replication | Physical (Sampling) |
| Legal structure | ETF |
| Investment approach | Long-only |
| Sustainability | Yes |
| Fund currency | EUR |
| Currency risk | Currency hedged |
| Volatility 1 year (in GBP) | 7.57% |
| Inception/ Listing Date | 24 November 2020 |
| Distribution policy | Accumulating |
| Distribution frequency | - |
| Fund domicile | Ireland |
| Fund Provider | Xtrackers |
| Fund Structure | Open-ended Investment Company (OEIC) |
| UCITS compliance | Yes |
| Administrator | State Street Custodial Services (Ireland) Limited |
| Investment Advisor | DWS Investments UK Limited |
| Custodian Bank | State Street Custodial Services (Ireland) Limited, Dublin 2 |
| Revision Company | Pricewaterhouse Coopers |
| Fiscal Year End | 31 December |
| Swiss representative | DWS CH AG |
| Swiss paying agent | Deutsche Bank (Suisse) SA |
| Germany | No tax rebate |
| Switzerland | No ESTV Reporting |
| Austria | Tax Reporting Fund |
| UK | UK Reporting |
| Italy | 26.0% |
| Indextype | - |
| Swap counterparty | - |
| Collateral manager | |
| Securities lending | No |
| Securities lending counterparty |
| US161175CV42 | 0.31% |
| US161175CU68 | 0.28% |
| Pfizer, 5.3% 19may2053, USD | 0.26% |
| AbbVie, 3.2% 21nov2029, USD | 0.21% |
| Pfizer, 4.75% 19may2033, USD | 0.20% |
| Amgen, 5.25% 2mar2033, USD | 0.20% |
| Microsoft, 2.525% 1jun2050, USD | 0.19% |
| AbbVie, 4.25% 21nov2049, USD | 0.19% |
| Salesforce, 5.55% 15mar2036, USD | 0.19% |
| Alphabet, 5.65% 15feb2056, USD | 0.19% |
| YTD | -8.12% |
| 1 month | -3.22% |
| 3 months | -3.70% |
| 6 months | -7.99% |
| 1 year | -8.89% |
| 3 years | +8.63% |
| 5 years | -16.20% |
| Since inception (MAX) | -23.31% |
| 2025 | +11.60% |
| 2024 | -6.19% |
| 2023 | +4.15% |
| 2022 | -16.80% |
| Volatility 1 year | 7.57% |
| Volatility 3 years | 9.41% |
| Volatility 5 years | 11.76% |
| Return per risk 1 year | -1.18 |
| Return per risk 3 years | 0.30 |
| Return per risk 5 years | -0.30 |
| Maximum drawdown 1 year | -10.77% |
| Maximum drawdown 3 years | -10.77% |
| Maximum drawdown 5 years | -25.74% |
| Maximum drawdown since inception | -31.46% |
| Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
|---|---|---|---|---|---|
| gettex | EUR | XZBE | - - | - - | - |
| XETRA | EUR | XZBE | XZBE GY XZBEEUIV | XZBE.DE XZBEEURINAV=SOLA |
| Fund name | Fund Size in m € (AuM) | TER p.a. | Distribution | Replication |
|---|---|---|---|---|
| iShares USD Corporate Bond UCITS ETF (Acc) | 4,779 | 0.20% p.a. | Accumulating | Sampling |
| iShares USD Corporate Bond UCITS ETF (Dist) | 3,251 | 0.20% p.a. | Distributing | Sampling |
| Vanguard USD Corporate Bond UCITS ETF Accumulating | 3,108 | 0.07% p.a. | Accumulating | Sampling |
| Xtrackers USD Corporate Bonds UCITS ETF 1D | 849 | 0.12% p.a. | Distributing | Sampling |
| Fidelity USD Corp Bond Research Enhanced PAB UCITS ETF ACC-GBP (hedged) | 577 | 0.25% p.a. | Accumulating | Full replication |